Atossa Therapeutics, Inc. (ATOS) announced on Tuesday the appointment of Mark Daniel as Chief Financial Officer to lead its capital strategy, as it prepares for commercial operations with (Z)-endoxifen.
In the pre-market activity on the Nasdaq, ATOS shares were trading 2.90% lower at $1.01. On Monday, the stocks had closed 2.78% lower at $1.05.
The clinical-stage biopharmaceutical company focused on breast cancer treatment noted that Daniel's deep treasury and capital-markets expertise would be relevant to its transition from clinical development to commercialisation.
Daniel, a senior finance leader, holds more than 25 years of experience in building forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science businesses.
Steven Quay, Atossa Chairman and Chief Executive Officer, stated that Daniel's skill set is exactly what they need to support the planned launch path for Z-endoxifen.
"I'm excited to help Atossa operationalise commercial readiness—from FP&A cadence and revenue forecasting to capital planning and investor engagement," said Daniel.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.